Posts Tagged ‘IPO’

Apellis IPO Road Show Takes Different Route

Putting Brakes on IPO, Apellis Lines Up Private Funding - Eye on Innovation

Putting Brakes on IPO, Apellis Lines Up Private Funding As the stock market took its 2016 nosedive, geographic atrophy drug developer Apellis Pharmaceuticals joined the parade of biotech companies that put the brakes on planned public offerings and turned back to private equity for the capital to drive their development programs. Apellis filed last fall…

Read More

EyeGate Finds New Paths to Dollars, Deal

OIS Podcast

EyeGate Pharmaceuticals had hit a wall. Its venture investors were tapped out, and the company needed capital to continue running clinical trials on its lead product. CEO Stephen From turned to the public markets, leading the company through a unique – and small IPO. With $4 million from the offering, the company signed an agreement…

Read More

Thinking About Market Cycles & Growth in the Ophthalmology Sector

Thinking About Market Cycles & Growth in the Ophthalmology Sector

A panel of Wall Street analysts offer their insights on the future performance of the public markets, including ophthalmology stocks at OIS@AAO in Las Vegas. Participants: Emmett T. Cunningham Jr., MD, PhD, MPH Dr. Cunningham, currently a Partner, joined Clarus in 2006 with more than 20 years of experience in the biomedical and biopharmaceutical sectors.…

Read More

A Record-Setting OIS

A Record-setting OIS

Last week’s Ophthalmology Innovation Summit drew nearly 1,000 attendees to Las Vegas’ Planet Hollywood hotel, marking the largest OIS event we’ve held yet. The size of the audience only added to the energy of what’s becoming a kickoff tradition for the American Academy of Ophthalmology’s annual meeting. Three dozen ophthalmology companies – representing Drug Delivery,…

Read More

Revenue Report Card for Recent IPO Class

Revenue Report Card for Recent IPO Class

As a rule, medical device companies have to demonstrate some level of commercial viability if they’re going to go public. A few are able to stage an IPO without meaningful revenue. However, most other device companies that have gone public lately have had to prove that customers are buying what they’re selling. And now that…

Read More

Were Glaukos’ IPO Investors Irrationally or Rightly Exuberant?

Were Glaukos’ IPO Investors Irrationally or Rightly Exuberant?

OIS Hot Shot Glaukos Corp. (NASDAQ—GKOS) raised over $100 million in an initial public offering (IPO) that highlighted extraordinary demand for ophthalmology’s minimally invasive glaucoma surgery (MIGS) market leader. In its initial SEC filing, Glaukos had proposed selling 5.4 million shares in the range $13 to $15 per share. With a positive investor reaction during…

Read More

2015 Review of the Ophthalmology Innovation Cycle

2015 Review of the Ophthalmology Innovation Cycle ASCRS 2015

Moderator: William J. Link, PhD Bill was Founder, Chairman and CEO of Chiron Vision, sold in 1997. Bill founded and served as President of American Medical Optics (AMO), sold in 1986. View Full Profile Panelists: Richard Lindstrom, MD Dr Richard L Lindstrom, Founder and attending surgeon at Minnesota Eye Consultants, Adjunct Clinical Professor Emeritus at…

Read More

Eleven’s Celniker Talks Leadership, Public Markets & Phase III Dry Eye Trials

OIS Podcast

Eleven Biotherapeutics capitalized on exciting technology and promising clinical results for its lead dry eye product to stage a successful IPO in 2014. Abbie C. Celniker, PhD, President and CEO, talks frankly about her leadership style, dealing with public investors and how she’s managing high expectations for lead product EBI-005. Podcast Guest Abbie C. Celniker,…

Read More

CEOs Share Lessons from IPOs

CEOs Share Lessons from IPOs

A panel of ophthalmology executives at the Ophthalmology Innovation Summit discuss the perks and pitfalls of going public. Moderator: David Guyer, MD Under Dr. Guyer’s leadership, Ophthotech raised more than $350 million in financing from May to September 2013, including a $192 million IPO, a multi-tranched $125 million royalty financing deal with Novo A/S and…

Read More

Private Funding Trends In Healthcare

Private Funding Trends In Healthcare

Jon Norris, senior vice president of Silicon Valley Bank, delivers a comprehensive report on the state of private opthalmology financing. Presenter: Jonathan Norris Jon Norris is a Managing Director with SVB Healthcare team, responsible for new business development. View Full Profile

Read More